Research Progress of Two New Antifibrotic Drugs for Idiopathic Pulmonary Fibrosis
WANG Chun-bin1,2, ZHANG Shuang1,2, ZHANG Qian1,2, ZHANG Xiang-lin1*
1. Department of Pharmacy, China-Japan Friendship Hospital, Beijing 100029, China; 2. Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
Abstract��Pirfenidone and nintadanib are two new anti-fibrotic drugs that have been shown to reduce the decline of lung function in patients with idiopathic pulmonary fibrosis (IPF) in multiple clinical trials,and have become first-line drugs for the treatment of IPF.However there are lack of references for how to choose between these two drugs. This article collected the latest research literatures related to pirfenidone or nintedanib,and summarized pharmacokinetics, pharmacological mechanism, clinical trials and safety profile of pirfenidone and nintedanib, so as to provide reference for clinical drug use. Evidences show both pirfenidone and nintedanib can reduce the decline of lung function and delay disease progression in mild-to-moderte IPF patients, and may have similar effects on severe IPF patients. There are large differences in pharmacological mechanisms, pharmacokinetics, and adverse events between these two new antifibrotic drugs. However, in terms of efficacy, there is no clear evidence to show which drug is better. Clinicians choosing drug should base on pharmacokinetic characteristics and adverse events between these two drugs.
������,��ˬ,��ٻ,������. �������Ϳ���ά��ҩ�������ط��Է���ά�����о���չ[J]. �й�ҩѧ��־, 2019, 54(9): 682-686.
WANG Chun-bin, ZHANG Shuang, ZHANG Qian, ZHANG Xiang-lin. Research Progress of Two New Antifibrotic Drugs for Idiopathic Pulmonary Fibrosis. Chinese Pharmaceutical Journal, 2019, 54(9): 682-686.
PARDO A, SELMAN M. Role of matrix metaloproteases in idiopathic pulmonary fibrosis . Fibrogenesis Tissue Repair, 2012, 5(suppl 1):1-5.
[2]
DU B R M. An earlier and more confident diagnosis of idiopathic pulmonary fibrosis. Eur Respir Rev, 2012, 21(124):141-146.
[3]
RAGHU G, COLLARD H R, EGAN J J, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 2011,183(6):788-824.
[4]
RAGHU G, ROCHWERG B, ZHANG Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline . Am J Respir Crit Care Med, 2015, 192(2):3-19.
[5]
HUANG N Y, DING L, WANG J, et al. Pharmacokinetics, safety and tolerability of pirfenidone and its major metabolite after single and multiple oral doses in healthy Chinese subjects under fed conditions. Drug Res (Stuttg), 2013, 63(8):388-395.
[6]
SHI S, WU J, CHEN H, et al. Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers. J Clin Pharmacol, 2007, 47(10):1268-1276.
[7]
AZUMA A. Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. Expert Rev Respir Med, 2010, 4(3):301-310.
[8]
DALLINGER C, TROMMESHAUSER D, MARZIN K, et al. Pharmacokinetic properties of nintedanib in healthy volunteers and patients with advanced cancer. J Clin Pharmacol, 2016, 56(11):1387-1394.
[9]
SCHMID U, LIESENFELD K H, FLEURY A, et al. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis. Cancer Chemother Pharmacol, 2018, 81(1):89-101.
[10]
XING J, ZHANG J. Research progress of nintedanib in the treatment of idiopathic pulmonary fibrosi . J China Pharm(�й�ҩ��),2015, 26(29):4174-4176.
[11]
CHEN Z,HU L A. Updated research on pathogenesis and pharmacological treatment of idiopathic pulmonary fibrosis . J Mod Med Health(�ִ�ҽҩ������־), 2016, 32(14):2175-2178.
[12]
SKOLD C M, BENDSTRUP E, MYLL�eRNIEMI M, et al. Treatment of idiopathic pulmonary fibrosis: a position paper from a nordic expert group . J Intern Med, 2017, 281(2):149-166.
[13]
CHEN Y Q, YAN Y J, CHOU M H, et al. Research progress on antifibrotic effect of pirfenidone . Clin Med J(�ٴ�ҩ��������־), 2016,14(5):1-7.
[14]
YANG H Y, LIANG Z A. The new achivements on treatment of IPF with nintedanib . Med J West China(����ҽѧ), 2017, 29(4):578-581.
[15]
AZUMA A, NUKIWA T, TSUBOI E, et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis . Am J Respir Crit Care Med, 2005, 171(9):1040-1047.
[16]
TANIGUCHI H, EBINA M, KONDOH Y, et al. Pirfenidone in idiopathic pulmonary fibrosis . Eur Respir J, 2010, 35(4):821-829.
[17]
NOBLE P W, ALBERA C, BRADFORD W Z, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY):two randomised trials . Lancet, 2011, 377(9779):1760-1769.
[18]
KING T E, BRADFORD W Z, CASTRO-BERNARDINI S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis . N Engl J Med, 2014, 370(22):2083-2092.
[19]
LOEH B, DRAKOPANAGIOTAKIS F, BANDELLI G P, et al. Intraindividual response to treatment with pirfenidone in idiopathic pulmonary fibrosis . Am J Respir Crit Care Med, 2015, 191(1):110-113.
[20]
HARARI S, CAMINATI A. Idiopathic pulmonary fibrosis: from clinical trials to real-life experiences . Eur Respir Rev, 2015, 24(137):420-427.
[21]
RAGHU G, JOHNSON W C, LOCKHART D, et al. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label phase �� study . Am J Respir Crit Care Med, 1999, 159(4 Pt 1):1061-1069.
[22]
SAKAMOTO S, ITOH T, MURAMATSU Y, et al. Efficacy of pirfenidone in patients with advanced-stage idiopathic pulmonary fibrosis . Intern Med, 2013, 52 (22):2495-2501.
[23]
SAKAMOTO S, MURAMATSU Y, SATOH K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study . Respirology, 2015, 20 (3):445-452.
[24]
RICHELDI L, COSTABEL U, SELMAN M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis . N Engl J Med, 2011, 365(12):1079-1087.
[25]
RICHELDI L, DU B R M, RAGHU G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis . N Engl J Med, 2014, 370 (22):2071-2082.
[26]
WUYTS W A, KOLB M, STOWASSER S, et al. First data on efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis and forced vital capacity of ��50% of predicted value . Lung, 2016, 194(5):739-743.
[27]
RICHELDI L, KREUTER M, SELMAN M, et al. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension . Thorax, 2018, 73(6):581-583.
[28]
REN H, WANG K, YANG H, et al. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis . Saudi Med J, 2017, 38 (9):889-894.
[29]
RUBINO C M, BHAVNANI S M, AMBROSE P G, et al. Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults . Pulm Pharmacol Ther,2009,22(4):279-285.
[30]
RICHELDI L, COTTIN V, DU B R M, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS�j trials . Respir Med, 2016, 113:74-79.
[31]
RODRGUEZ-PORTAL J A. Efficacy and safety of nintedanib for the treatment of idiopathic pulmonary fibrosis: an update . Drugs RD, 2018, 18 (1):19-25.
[32]
SERGEW A, BROWN K K. Advances in the treatment of idiopathic pulmonary fibrosis . Expert Opin Emerg Drugs,2015, 20(4):537-552.
[33]
LOVEMAN E, COPLEY V R, SCOTT D A, et al. Comparing new treatments for idiopathic pulmonary fibrosis--a network meta-analysis . BMC Pulm Med, 2015, 15(1):37.
[34]
SAKAMOTO S, MURAMATSU Y, SATOH K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study . Respirology, 2015, 20 (3):445-452.
[35]
BEHR J, BENDSTRUP E, CRESTANI B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial . Lancet Respir Med, 2016, 4 (6):445-453.
[36]
OGURA T, TANIGUCHI H, AZUMA A, et al. Safety and pharmacokinetics of nintedanib and pirfenidone in idiopathic pulmonary fibrosis . Eur Respir J, 2015, 45 (5):1382-1392.
[37]
ROSELYNE B, CITTERIO-QUENTIN A, MOULSMA M, et al. ITPA activity in adults and children treated with or without azathioprine: relationship between TPMT activity, thiopurine metabolites and co-medications . Ther Drug Monit, 2017, 39 (5):483-491.
2019, Vol. 54 
